Mergers and Acquisitions

(Image: Getty/Radachynskyi)

Recro spins out Baudax to boost CDMO focus

By Vassia Barba

Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.

(Image: Getty/BobHemphill)

Takeda sheds products in emerging markets in $200m deal

By Ben Hargreaves

Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.

(Image: Getty/Robert Daly)

UCB set to buy Ra Pharma for $2.1bn

By Ben Hargreaves

With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.

Follow us

Products

View more

Webinars